S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Farhad Ravandi,Susan O'Brien,Jorge E. Cortes,Deborah M. Thomas,Rebecca Garris,Stefan Faderl,Jan A. Burger,Michael Rytting,Alessandra Ferrajoli,William G. Wierda,Srdan Verstovsek,Richard E. Champlin,Partow Kebriaei,Deborah McCue,Xuelin Huang,Elias Jabbour,Guillermo Garcia-Manero,Zeev Estrov,Hagop M. Kantarjian +18 more
TL;DR: The long‐term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established.
Journal ArticleDOI
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
Elihu H. Estey,Francis J. Giles,Miloslav Beran,Susan O'Brien,Sherry Pierce,Stefan Faderl,Jorge E. Cortes,Hagop M. Kantarjian +7 more
TL;DR: Mylotarg appears active in APL, and repeated administration is feasible, as well as well tolerated, and none of the 7 patients evaluated subsequently have reverted to PCR positivity.
Journal ArticleDOI
Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
Stefan Faderl,Meir Wetzler,David A. Rizzieri,Gary J. Schiller,Madan Jagasia,Robert K. Stuart,Siddhartha Ganguly,David Avigan,Michael Craig,Robert H. Collins,Michael B. Maris,Tibor Kovacsovics,Stuart L. Goldberg,Karen Seiter,Parameswaran Hari,Jochen Greiner,Norbert Vey,Christian Recher,Farhad Ravandi,Eunice S. Wang,Michael J. Vasconcelles,Dirk Huebner,Hagop M. Kantarjian +22 more
TL;DR: Although the primary end point of OS did not differ between arms, Clo+Ara-C significantly improved response rates and EFS, and the role of clofarabine in the treatment of adult patients with AML continues to be investigated.
Journal ArticleDOI
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
Deborah A. Thomas,Susan O'Brien,Jeffrey L. Jorgensen,Jorge E. Cortes,Stefan Faderl,Guillermo Garcia-Manero,Srdan Verstovsek,Charles A. Koller,Sherry Pierce,Yang Huh,William G. Wierda,Michael J. Keating,Hagop M. Kantarjian +12 more
TL;DR: CD20 expression in de novo adult precursor B-lineage ALL appears to be associated with a poor prognosis, and incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation.
Journal ArticleDOI
Phase II study of dasatinib in philadelphia chromosome - Negative acute and chronic myeloid diseases, including systemic mastocytosis
Srdan Verstovsek,Ayalew Tefferi,Jorge E. Cortes,Susan O'Brien,Guillermo Garcia-Manero,Animesh Pardanani,Cem Akin,Stefan Faderl,Taghi Manshouri,Deborah A. Thomas,Hagop M. Kantarjian +10 more
TL;DR: Data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.